Results 211 to 220 of about 39,539 (240)
Some of the next articles are maybe not open access.
Glycoprotein conjugate vaccines
Vaccine, 1999The polysaccharide capsule which surrounds bacterial species like Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Salmonella typhi, is a potent virulence factor. It protects the bacterium from phagocytosis, but capsule specific antibodies plus complement binding to the capsule opsonise the organism for phagocytosis and ...
openaire +2 more sources
Meningococcal conjugate vaccines
Expert Opinion on Biological Therapy, 2005Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do
openaire +2 more sources
Pneumococcal Conjugate Vaccines
1995The development of multivalent pneumococcal vaccines for the prevention of both systemic and noninvasive pneumococcal diseases in infants, older adults, and immunecompromised individuals has gained increasing importance over the last decade. The rising cost of medical care has renewed interest in prevention instead of cure for a disease and in many ...
openaire +2 more sources
Early immunization with conjugate vaccines
Vaccine, 1998Conjugate vaccines have been used during the neonatal period or in early infancy in order to test their safety and immunologic behaviour. Adverse events even in neonates and premature babies have been mild and spontaneously resolving. Anticapsular antibody concentrations after first doses of Hib conjugates in early infancy are generally low, but ...
J, Eskola, H, Käyhty
openaire +2 more sources
The promise of conjugate vaccines for Africa
Vaccine, 2007Capsular polysaccharide (PS) vaccines against Neisseria meningitidis and Streptococcus pneumoniae have proven safe and effective. Moreover, experience with N. meningitidis, Haemophilus influenzae type b (Hib) and S. pneumoniae conjugate vaccines has demonstrated that immunogenicity of PS vaccines can be greatly improved by chemical conjugation to a ...
Marie Paule, Kieny, F Marc, LaForce
openaire +2 more sources
Revue medicale de Bruxelles, 2002
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +2 more sources
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +2 more sources
Conjugated Heptavalent Pneumococcal Vaccine
The Annals of Pharmacotherapy, 2002OBJECTIVE: To review the immunogenicity, efficacy, and safety of the heptavalent conjugated pneumococcal vaccine (PCV7). DATA SOURCES: A MEDLINE search (1993–August 2001) of research limited to humans published in the English language ...
Vinita B, Pai +2 more
openaire +2 more sources
Conjugate pneumococcal vaccines: an overview
Medical Journal of Australia, 2000A seven-valent conjugate pneumococcal vaccine has been shown to have dramatic efficacy against invasive pneumococcal disease and lesser efficacy against otitis media and pneumonia. This vaccine was licensed for use in infants in the United States in February 2000 and is recommended there for routine use in infants and catch-up vaccination in high-risk ...
openaire +2 more sources
The pneumococcal protein conjugate vaccines
The Journal of Pediatrics, 2000to develop the first licensed pneumococcal vaccine, consisting of 14 purified capsular polysaccharide antigens representing the most prevalent disease-associated serotypes. Coverage was improved by the addition of 9 more purified polysaccharide antigens, resulting in the currently licensed 23valent pneumococcal capsular polysaccharide vaccine.
T R, Peters, K M, Edwards
openaire +2 more sources
Pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 1999J, Eskola, M, Anttila
openaire +4 more sources